|
Targacept Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and …
EON: Enhanced Online News (press release) TC-6987 demonstrated a potent anti-inflammatory response in a variety of preclinical studies conducted by Targacept, including models of asthma and diabetes … Targacept to begin phase 2 trials for its anti-inflammatory drug compound Targacept starts new trial for diabetes drug |
View full post on asthma – Google News